Carbamazepine vs phenobarbitone: Time to treatment failure (any reason related to treatment) All participants Range of
Carbamazepine probably leads to lower time to treatment failure (any reason related to treatment) All… compared with phenobarbitone (moderate certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Carbamazepine vs phenobarbitone Time to treatment failure (any reason related to treatment) All participants Range of · adults and children with newly onset focal or generalised epilepsy Carbamazepine probably leads to lower time to treatment failure (any reason related to treatment) All… compared with phenobarbitone (moderate certainty). Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review (2018) · Cochrane Headline outcomes only | HR 0.66 [0.5, 0.86] | 4 studies · 676 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review 2018 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.